New insider activity at Mirum Pharmaceuticals ( (MIRM) ) has taken place on March 7, 2025.
Director Patrick Heron has made a significant investment in Mirum Pharmaceuticals by purchasing 1,602 shares of the company’s stock, amounting to a total value of $72,711.
Recent Updates on MIRM stock
Mirum Pharmaceuticals has reported strong financial performance in its recent Q4 earnings call, with total net product sales reaching $336.4 million for 2024, a significant increase from the previous year. The company highlighted the FDA approval of CTEXLI for cerebrotendinous xanthomatosis, which provides seven years of market exclusivity, and the expansion of LIVMARLI’s market, contributing to a 50% increase in sales. Despite challenges in penetrating the Alagille syndrome market and high operating expenses, Mirum’s robust pipeline advancements, including positive interim results for Volixibat, have led to a positive outlook. Analysts at Morgan Stanley and Baird have raised their price targets for Mirum, citing the company’s strong financial results, ongoing pipeline progress, and management’s reiterated optimistic sales guidance for 2025 as key reasons for their updates.
More about Mirum Pharmaceuticals
YTD Price Performance: 6.18%
Average Trading Volume: 508,666
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.22B
Questions or Comments about the article? Write to editor@tipranks.com